Leishmaniasis in the Sudan: A literature review with emphasis on clinical aspects

Tropical Medicine and International Health

Volumn 5, Issue 8, 2000, Pages 553-562

  Osman, Omran F ^a   Kager, Piet A ^b   Oskam, Linda ^c  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

Clinical features; Diagnosis; Entomology; Kala azar; Leishmaniasis; PKDL; Sudan; Treatment

Indexed keywords

DISEASE CONTROL; HEALTH SERVICES; LEISHMANIASIS; LITERATURE REVIEW;

CLINICAL FEATURE; HUMAN; LEISHMANIA; LEISHMANIASIS; POLYMERASE CHAIN REACTION; REVIEW; SUDAN;

AGGLUTINATION TESTS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DISEASE OUTBREAKS; HUMANS; LEISHMANIASIS; POLYMERASE CHAIN REACTION; SUDAN;

SUDAN;

NASO HEXACANTHUS; PROTOZOA;

EID: 0033836685     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2000.00598.x     Document Type: Review

References (101)

1. Serodiagnosis of visceral leishmaniasis in an endemic area of the Sudan
2. Cutaneous leishmaniasis in the Sudan
3. Sudan mucosal leishmaniasis
4. Epidemic of cutaneous leishmaniasis in northern Sudan
5. Potential of a direct agglutination test (DAT) for detection of visceral leishmaniasis in a known endemic area in Sudan
6. The relationship between human and animal strains of Leishmania from the Sudan
7. Outbreak of visceral leishmaniasis on the western bank of the White Nile-Sudan, report and clinical studs
8. Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: A comparison with direct microscopy of smears and sections from lesions
9. Diagnosis of visceral leishmaniasis by the polymerase chain reaction using blood, bone marrow and lymph node samples from patients from the Sudan
10. A case of parasitic granuloma in which development forms of Leishmania tropica were present
11. Some observations on the epidemiology of kala-azar in the Sudan
12. Epidemic visceral leishmaniasis in southern Sudan: Identity and systematic position of the parasites from patients and vectors
13. Visceral leishmaniasis in Sudan. A delayed development disaster?
14. New perspectives on a subclinical form of visceral leishmaniasis
15. A prospective study of visceral leishmaniasis in an endemic area of Brazil
16. Some remarks on kala-azar in the Sudan
17. Intravenous injection of antimony tartrate
18. A killing disease epidemic among displaced Sudanese population identified as visceral leishmaniasis
19. Human leishmaniases: Epidemiology and public health aspects
20. Serodiagnosis of Sudanese visceral and mucosal leishmaniasis: Comparison of ELISA-immunofluorescence and indirect haemagglutination
21. ELISA using intact promastigotes for immunodiagnosis of kala-azar
22. Visceral leishmaniasis: Pathology and pathogenesis
23. Visceral leishmaniasis in the Sudan: Clinical and haematological features
24. Post kala-azar dermal leishmaniasis in the Sudan: Clinical features, pathology and treatment
25. Post-kala-azar dermal leishmaniasis in the absence of active visceral leishmaniasis
26. Distinguishing post-kala-azar dermal leishmaniasis from leprosy: Experience in the Sudan
27. Kala-azar in western Upper Nile province in the southern Sudan and its spread to a nomadic tribe from rhe north
28. Post kala-azar ocular leishmaniasis
29. Sudanese mucosal leishmaniasis: Epidemiology, clinical features, diagnosis, immune responses and treatment
30. Recent observations on the epidemiology of kala-azar in the Eastern and Central States of the Sudan
31. Identification of Leishmania donovani using a polymerase chain reaction in patient and animal material obtained from an area of endemic kala-azar in the Sudan
32. Infection rates of Leishmania donovani in Phlebotomus orientalis from a focus of visceral leishmaniasis in eastern Sudan
33. Environmental determinants of the distribution of Phlebotomus orientalis in Sudan
34. Phlebotomine sandflies in a focus of visceral leishmaniasis in a border area of eastern Sudan
35. Evidence for active transmission of visceral leishmaniasis within a village in eastern Sudan
36. A comparison of the direct agglutination test and enzyme-linked immunosorbent assay in the serodiagnosis of leishmaniasis in the Sudan
37. Studies on the leishmaniases in the Sudan. 1. Epidemic of cutaneous leishmaniasis in Khartoum
38. Studies on the leishmaniases in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis
39. Studies on the leishmaniases in the Sudan. 3. Clinical and parasitological studies on visceral and mucosal leishmaniasis
40. Congenital kala-azar and leishmaniasis in the placenta
41. Identification of Leishmania from mucosal leishmaniasis by recombinant DNA
42. A case of African histoplasmosis from Sudan
43. Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin condirions
44. Neurologic changes in visceral leishmaniasis
45. An outbreak of acute kalaazar in a nomadic tribe in western Sudan: Features of the disease in a previously non-immune population
46. Tinea versicolor and visceral leishmaniasis
47. Clinical observations on kala-azar in the Fung province of the Anglo-Egyptian Sudan
48. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya
49. Leishmaniasis in the Sudan Republic. 30. Final epidemiologic report
50. Diversity among Leishmania isolates from the Sudan: Isoenzyme homogeneity of L.donovani versus heterogeneity of L. major
51. Detection and characterisation of Leishmania in tissues of patients with post kala-azar dermal leishmaniasis using a specific monoclonal antibody
52. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: Management of those who did not respond
53. Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis
54. Primary cutaneous sore in a case of kala-azar
55. Studies in leishmaniasis in the Anglo-Egyptian Sudan. VIII. Some observations on the chemotherapy of kala-azar
56. Studies in leishmaniasis in the Anglo-Egyptian Sudan. XII. Attempts to find a reservoir host
57. Preliminary notes on dermal leishmaniasis in the Anglo-Egyptian Sudan
58. Studies in leishmaniasis in the Anglo-Egyptian Sudan. II. The skin and lymph gland in kala-azar
59. Studies in leishmaniasis in the Anglo-Egyptian Sudan. IV. Punctate rash in treated cases
60. East African kala-azar with special reference to the pathology, prophylaxis and treatment
61. Kala-azar commission to investigate the prevalence and cause of the disease in the Eastern Sudan (2) Pathological report
62. WHO warns of epidemic leishmaniasis
63. Kala azar in eastern Upper Nile Province, southern Sudan
64. Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis
65. Development and application of the polymerase chain reaction for the detection and identification of Leishmania parasites in clinical material. Archives de l'Institut
66. Phlebotomus martini, a probable vector of kala-azar in Kenya
67. Biochemical and molecular characterization of Leishmania parasites isolated from an endemic focus in eastern Sudan
68. Use of PCR on lymph-node samples as test of cure of visceral leishmaniasis treatment
69. Evaluation of PCR for diagnosis of visceral leishmaniasis
70. Use of PCR for diagnosis of post-kala-azar dermal leishmaniasis
71. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment
72. Visceral leishmaniasis in southern Sudan
73. Phlebotomus sandflies of the Paloich Area in the Sudan (Diptera, Psychodidae)
74. Leishmaniasis in the Sudan Republic. XVIII. Parasitemia in kala-azar
75. Early phases of an outbreak of kala-azar in the Southern Fung
76. Incrimination of Phlebotomus (Laroussius) orientalis as a vector of visceral leishmaniasis in western Upper Nile Province, southern Sudan
77. Visceral leishmaniasis in southern Sudan: Status of healthy villagers in epidemic conditions
78. Liposomal amphotericin B (Ambisome) in the treatment of complicated kala-azar under field conditions
79. The epidemic of visceral leishmaniasis in Western Upper Nile, southern Sudan: Course and impact from 1984 to 1994
80. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources
81. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone
82. Kala-azar in the Sudan: Clinical and immunological manifestations
83. Visceral leishmaniasis in the Sudan: Comparative parasitological methods of diagnosis
84. Visceral leishmaniasis in Sudan. Clinical features
85. An epidemic of kala-azar in the Upper Nile province of the Anglo-Egyptian Sudan
86. Leishmaniasis in the Sudan republic. VI. Clinical and laboratory aspects of kala-azar in hospitalized patients from Upper Nile province
87. A randomised comparison of branded and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
88. Present epidemiological situation of kalaazar in the Republic of Sudan
89. Kala-azar in displaced people from southern Sudan: Epidemiological, clinical and therapeutic findings
90. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kalaazar
91. Endemic kala-azar in eastern Sudan: Post-kala-azar dermal leishmaniasis
92. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leish-maniasis
93. The direct agglutination test for diagnosis of visceral leishmaniasis under field conditions in Sudan: Compatison of aqueous and freeze-dried antigens
94. Direct agglutination test for diagnosis and sero-epidemiological survey of kalaazar in the Sudan
95. Kala-azar: A comparative study of parasitological methods and the direct agglutination test in diagnosis
96. The treatment of kala-azar in the Sudan with sodium stibogluconate: A randomized trial of three dosage regimens